Plain-English translation of NCT06897930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Erythematosus, Systemic research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a clinical trial testing a new medication called , which is a type of immunotherapy that uses your own immune cells to fight lupus. Researchers are studying whether this treatment is safe and whether it can help people whose lupus has not improved with standard medications. The trial will first test the treatment's safety and then measure how well it actually works.
Some people with lupus don't respond well enough to current treatments and continue to suffer from active disease. This medication represents a new approach to lupus treatment, and researchers want to understand whether it can help patients who have already tried multiple standard therapies without adequate relief.
You likely qualify if…
You likely don't qualify if…
You will receive a single infusion of the medication after your own immune cells are collected and modified in the laboratory. The trial has two phases: first, researchers will closely monitor a small group to ensure the treatment is safe, and then a larger group will receive the treatment to test whether it actually improves lupus symptoms. You will need to attend multiple clinic visits for monitoring, blood tests, and evaluations of how well you're responding.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States